StockData
Exagen Inc. logo

Exagen Inc. (XGN) company profile

XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3010% above fair value
$3.76−0.01 (-0.27%)

Close on Nov 17, 2026Market cap $91.09MP/E –Yield –

About Exagen

Services-Medical Laboratories, SIC 8071

Exagen is a medical technology company that develops and commercializes diagnostic, prognostic, and monitoring testing products focused on complex rheumatic and autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. The company provides a suite of ten commercialized tests under the AVISE brand name, featuring its connective tissue disease panel alongside specialized assays for disease prognosis, vasculitis, and therapeutic drug monitoring. Its testing services support rheumatologists, primary care physicians, other medical specialists, hospitals, and healthcare systems.

The company conducts its operations in the United States, where it utilizes a dedicated sales organization to reach approximately 6,000 rheumatologists nationwide. Testing procedures are conducted through its central specialty laboratory. The provided text does not state the location of the company's headquarters or provide counts of additional facilities.

Summary of the business section of Exagen's latest annual report, written by StockData.

Company profile

Company

Legal name
Exagen Inc.
Founded
2002
Headquarters
Vista, CA
Address
1261 Liberty Way 92081
Phone
(760) 560-1501
Website
exagen.com
Employees
220, Dec 31, 2025
Industry
Services-Medical Laboratories
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BDO USA, P.C., San Diego, California

Stock & identifiers

Ticker
XGN
Exchange
Nasdaq
IPO date
Sep 19, 2019
Shares outstanding
24M, Jul 30, 2026
Public float
$153.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1274737
CUSIP
30068X103
ISIN
US30068X1037
FIGI
BBG00178FZY1
Share class FIGI
BBG001TCQVF6
LEI
549300JV2CYDOME5OO17
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
John AballiPresident and CEO, Director845,941
Jeffrey G. BlackChief Financial Officer324,910
Tina Susan NovaDirector–
Bruce C. RobertsonDirector–
Paul KimDirector–
Chas McKhannDirector7,500
Frank StokesDirector–
Scott D. KahnDirector–
Ana HookerDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.40M$2.86M$746.19K$253–
FY2024$1.18M$1.98M$905.66K$168–
FY2023$931.95K$775.33K$984.54K$82–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
John Aballi
President, Chief Executive Officer, Director and former Interim Chief Financial Officer(6)
$540.00K$402.75K$203.02K$237.60K$17.50K$1.40M+18%
Jeffrey Black
Chief Financial Officer and Corporate Secretary(7)
$465.00K$53.70K$27.07K$186.00K$14.42K$746.19K-27%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had a total of 220 employees: 216 full-time employees and 4 part-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 14, 2022Late filingNotification of late filing
Sep 13, 2019ListingRegistration of securities on an exchange (Form 8-A)
May 18, 2017Name changeName changed from EXAGEN DIAGNOSTICS INC to Exagen Inc.

See a number that looks wrong?